Practical chemistry for radiolabelling biomolecules
Biomolecules exhibit excellent targeting properties (e.g. high affinity and specificity) prompting their use in imaging and therapeutic radiopharmaceuticals. Their molecular structure can be irreparably damaged if harsh reaction conditions are used in their radiolabelling (e.g. high temperature, extremes of pH). Mild chemistries are have been exemplified as effective for radiolabelling biomolecules without perturbing their biological function, however this toolbox of chemistry needs to be expanded for greater synthetic flexibility and improved radiolabelling properties. We are developing new radiochemistry to synthesise radioconjugates with an emphasis towards GMP compliant chemistry for clinical translation.
Advancements in automated radiosynthesis
Automated radiosynthesis is required for the production of most GMP compliant radiopharmaceuticals. Complex radiolabelling procedures can be challenging to automate which can prevent their transition into clinical studies. We develop new automated procedures and devices to address challenges in the radiosynthesis and purification of radiolabelled small-molecules and biomolecules. These advancements will facilitate the bench-to-bedside journey of our novel radiopharmaceuticals.
Radiopharmaceuticals for clinical demand
Working together with biology and clinical colleagues, we develop novel radiopharmaceuticals to help address important clinical questions, to improve the diagnosis and management of diseases like cancer.